SCHEMBL5865544

SCHEMBL5865544

COc1ccc2c(c1)C=C(c1cc(NOC(=O)/C=C/C(=O)ONc3ccnc(C4=Cc5cc(OC)ccc5CC4)c3)ccn1)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.47
CYP11B1 P15538 3/20 0.41
CYP19A1 P11511 2/20 0.38
PTGS2 P35354 1/20 0.35
KDM1A O60341 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SYK P43405 2/20 0.33
MAPT P10636 4/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CCR1 P32246 1/20 0.32
CCR5 P51681 1/20 0.32
CCR8 P51685 1/20 0.32
KDM4E B2RXH2 4/20 0.32
NQO2 P16083 2/20 0.32
MTNR1A P48039 2/20 0.32
MTNR1B P49286 2/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865309 0.86 CNR1 (0.33) CYP11B2
SCHEMBL5864811 0.80 KDM1A (0.34) CYP19A1KDM1AHDAC1HDAC6MAPT
Fumaric Acid SCHEMBL5865541 0.78 CYP11B2 (0.48) CYP11B2CYP11B1CYP19A1PTGS2MAPT
Fumaric Acid SCHEMBL5865549 0.78 CYP11B2 (0.48) CYP11B2CYP11B1CYP19A1PTGS2MAPT
SCHEMBL5865386 0.77
SCHEMBL5865162 0.75 CYP11B2 (0.54) CYP11B2CYP11B1CYP19A1PTGS2MAPT
SCHEMBL5865264 0.70 CYP19A1 (0.35) CYP11B2CYP11B1CYP19A1PTGS2SMN1; SMN2
SCHEMBL5865017 0.69 CYP11B2 (0.31) CYP11B2MAPTALDH1A1L3MBTL1POLB
SCHEMBL5865377 0.68 CYP19A1 (0.33) CYP11B2CYP11B1CYP19A1PTGS2
Fumaric Acid SCHEMBL5865432 0.68 GRIN2D (0.40) CYP11B2CYP11B1CYP19A1PTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C CYP11B2 317/4885CYP11B1 359/4885CYP19A1 1693/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C CYP11B2 317/4885CYP11B1 359/4885CYP19A1 1693/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C CYP11B2 379/4885CYP11B1 445/4885CYP19A1 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.